But Dr David Rind, the chief medical officer for the Institute for Clinical and Economic Review research group, suggests tirzepatide may be marketed at around $1,100 a month — or $13,000 annually. Wegovy is listed for around $1,500 monthly, while Saxenda costs about $1,350 for a 30-day prescription. Some insurance companies will cover the drugs for treating type 2 diabetes, but most are expected to shy away from covering them for weight loss — meaning patients will need to pay out of pocket.